LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Trauma/€2M Raised for Fracture Treatment Sensor
Trauma

€2M Raised for Fracture Treatment Sensor

May 20, 2024 2 min read Premium comments

Advertisement

€2M Raised for Fracture Treatment Sensor
ADEPTH / Courtesy of SLAM Orthopedic
Secondary#adepth#slamorthopedic

Netherlands-based SLAM Orthopedic has effectively raised a seed investment of €2 million.

SLAM Orthopedic is a medical device company dedicated to developing advanced sensor systems for fracture care by surgeons. Rising Star Venture Partners led the funding round and was joined by informal investors and the Zeeuws Participatie Fonds.

SLAM Orthopedic will use the funds to complete product development of ADEPTH®. ADEPTH, per the company website, is an “automated screw length measurement system for use during surgical treatment of fractures.” Surgeons treating fracture patients can use the add-on sensor to measure and identify the required implant size.

OTW spoke with SLAM Orthopedic Co-founder and CEO Just Schornagel about the use of the funds. Schornagel told OTW, “We’ll use the funds to grow our team, finalize development of the device (make it resterilizable in the autoclave, finish the user interface), then also perform new wet-lab studies to validate performance and CE-certification as a Class IIa device under the MDR (FDA will follow in 2026).”

Schornagel continued, “The funds will then also be used to set up a production line and start sales with the first hospitals that signed up for our pilot program (14 so far).”

SLAM Orthopedic is already working with the department of trauma surgery of ErasmusMC to validate the ADEPTH system in a first-in-human clinical trial. Per the press release, SLAM Orthopedic plans to bring the ADEPTH system to the European market mid-2025.

OTW also spoke with Schornagel about what makes SLAM Orthopedic’s technology different from competitor technology. Schornagel explained to OTW, “What makes our technology stand out is that the sensor device is compatible with existing drill machines and drill bits (with the AO Quick Connect). This means surgeons can keep working with their current instruments and hospitals don’t have to purchase new equipment.”

Schornagel continued, “What is also unique is that we can perform the measurement fully contactless (using lasers and force transducers). This means that surgeons still have 100% of their tactile feedback that they rely on to understand their position in the body. No calibration is necessary before you start drilling. You just pick up the drill, the sensor automatically detects this and switches to on mode and after you retrieve the drill automatically displays the implant length.”

Schornagel continued, “All of the above means that our system is designed to be easily integrated in a surgeon’s current workflow. Having a surgeon co-founder, but also involving a lot of experienced trauma and orthopedic surgeons in early stages of the development process were fundamental to end up with—what we believe is a user-friendly product.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy